BICYCLIC-HETEROCYCLE DERIVATIVES AND RELATED USES
The present disclosure relates to compounds of Formula (I′): and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for modulating orexin receptor activity and may be used in the treatment of disorders in which orexin receptor activity is implicated, such as narcolepsy, a hypersomnia disorder, a neurodegenerative disorder, a symptom of a rare genetic disorder, a mental health disorder, a metabolic syndrome, osteoporosis, cardiac failure, coma, or a complication in emergence from anaesthesia.
1 . (canceled)
2 . A compound of Formula (I′):
or a pharmaceutically acceptable salt thereof, wherein:
Z is —NH—;
X is —C(R X1 ) 3 or —N(R X2 ) 2 ;
each R X1 independently is H, —CN, —OH, halogen, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkyl, or C 3 -C 6 cycloalkyl, wherein the C 1 -C 6 alkyl is optionally substituted with C 1 -C 6 alkoxy,
or two R X1 together with the atom to which they are attached form a C 3 -C 8 cycloalkyl or 4- or 5-membered heterocycloalkyl, wherein the C 3 -C 8 cycloalkyl is optionally substituted with one or more halogen;
each R X2 independently is H, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, or —(CH 2 ) n —C 3 -C 6 cycloalkyl, wherein the cycloalkyl is optionally substituted with one or more halogen,
or two R X2 together with the atom to which they are attached form a 4-membered heterocycloalkyl optionally substituted with C 1 -C 6 alkoxy;
Ar 1 is C 6 aryl substituted with one or more R 3 ;
R 3 is halogen;
R 1 is C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, or C 3 -C 7 cycloalkyl optionally substituted with one halogen;
R 2 is C 6 aryl optionally substituted with one or more R 2S ;
each R 2S independently is halogen;
R 4a is H;
R 4b is H; and
n is 0, 1, or 2.
3 - 30 . (canceled)
31 . The compound of claim 2 , wherein X is —C(R X1 ) 3 .
32 . The compound of claim 2 , wherein X is —N(R X2 ) 2 .
33 . The compound of claim 2 , wherein each R X1 independently is —CN, —OH, halogen, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, or C 3 -C 6 cycloalkyl.
34 . The compound of claim 2 , wherein each R X2 independently is C 1 -C 6 alkyl or C 1 -C 6 haloalkyl.
35 . The compound of claim 2 , wherein Ar 1 is C 6 aryl substituted with one R 3 .
36 . The compound of claim 2 , wherein Ar 1 is C 6 aryl substituted with two R 3 .
37 . The compound of claim 2 , wherein R 3 is F.
38 . The compound of claim 2 , wherein R 1 is C 1 -C 6 alkyl or C 1 -C 6 haloalkyl.
39 . The compound of claim 2 , wherein R 2 is C 6 aryl.
40 . The compound of claim 2 , wherein R 2 is C 6 aryl substituted with one or more R 2S .
41 . The compound of claim 40 , wherein each R 2S independently is F.
42 . The compound of claim 2 , wherein the compound is of Formula (I-1a) or (1-1b):
or a pharmaceutically acceptable salt thereof,
wherein p is 0, 1, 2, 3, or 4 and q is 0, 1, 2, 3, 4, or 5.
43 . The compound of claim 2 , wherein the compound is selected from:
or a pharmaceutically acceptable salt thereof.
44 . A pharmaceutical composition comprising the compound of claim 2 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable diluent or carrier.
45 . A method of modulating orexin-2 receptor activity, comprising contacting a cell with an effective amount of the compound of claim 2 or a pharmaceutically acceptable salt thereof.
46 . A method of treating a disease or disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the compound of claim 2 or a pharmaceutically acceptable salt thereof.
47 . The method of claim 46 , wherein the disease or disorder is associated with an implicated orexin receptor.
48 . The method of claim 46 , wherein the disease or disorder is narcolepsy, a hypersomnia disorder, a neurodegenerative disorder, a neurological disorder, a symptom of a rare genetic disorder, a psychiatric disorder, a mental health disorder, a circadian rhythm disorder, a metabolic syndrome, osteoporosis, cardiac failure, coma, or facilitating emergence from anesthesia.
49 . The method of claim 46 , wherein the disease or disorder is narcolepsy, idiopathic hypersomnia, or sleep apnea.